Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors

Background This study evaluated the safety, tolerability, pharmacokinetics, immunogenicity and antitumor activity of single and multiple doses of nivolumab in Japanese patients with malignant solid tumors. Subjects and Methods This was an open-label, dose-escalation study in 17 patients with advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Noboru, Nokihara, Hiroshi, Yamada, Yasuhide, Shibata, Takashi, Tamura, Yosuke, Seki, Yoshitaka, Honda, Kazunori, Tanabe, Yuko, Wakui, Hiroshi, Tamura, Tomohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352798/
https://www.ncbi.nlm.nih.gov/pubmed/27928714
http://dx.doi.org/10.1007/s10637-016-0411-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352798/
https://www.ncbi.nlm.nih.gov/pubmed/27928714
http://dx.doi.org/10.1007/s10637-016-0411-2

Ejemplares similares